首页 > 最新文献

Substance Abuse: Research and Treatment最新文献

英文 中文
Lean/Sizzurp Ingredients, Use, and Coping With Mental Health Symptoms. 精益/Sizzurp成分、使用和应对心理健康症状。
IF 2.1 Q3 SUBSTANCE ABUSE Pub Date : 2023-09-22 eCollection Date: 2023-01-01 DOI: 10.1177/11782218231195226
Orrin D Ware

The substance combination of codeine and promethazine, commonly termed lean/sizzurp, has been identified as a method that some individuals use to cope with PTSD and other mental health symptomology. A sample of 1423 adults with self-reported past year lean use was recruited from substance-related Reddit pages to complete a survey about lean, including information about using lean to cope with emotions, thoughts, or feelings. To be included in the sample, persons needed to: (1) be ⩾18 years old, (2) report past year lean use, (3) complete lean use screeners, and (4) pass data quality checks (eg, bot detection). As Reddit is an online forum, no geographic restrictions were placed on study participation. Data on demographic characteristics, lean use, and mental health disorder symptomology were captured from participants. Logistic regression models included anxiety, depression, and trauma as independent variables along with covariates to examine using lean to cope with emotions, thoughts, or feelings in the past 30 days. Most participants were male (n = 1102; 77.4%), with an average age of 26.9 (SD = 5.2) years. Most participants used included codeine as an ingredient in lean (n = 1060; 74.5%); promethazine was added as an ingredient by 31.7% of the sample (n = 451), and the combination of codeine and promethazine was included as ingredients by 13.5% (n = 192) of the sample. Participants with anxiety, lifetime trauma exposure, and who were female had increased odds of using lean to cope with emotions, thoughts, or feelings in the past 30 days. Those with depression and unstable housing exhibited decreased odds of using lean to cope with emotions, thoughts, or feelings in the past 30 days. This study recruited persons via social media to learn more about lean use, especially lean use to cope with mental health symptoms; future population-level studies are needed.

可待因和异丙嗪的物质组合,通常被称为瘦肉/西珠普,已被确定为一些人用来应对创伤后应激障碍和其他心理健康症状的一种方法。从物质相关的Reddit页面中招募了1423名自报去年使用过精益的成年人作为样本,以完成一项关于精益的调查,包括使用精益来应对情绪、想法或感受的信息。要被包括在样本中,人需要:(1)是⩾18 岁,(2)报告过去一年的精益使用,(3)完成精益使用筛选,(4)通过数据质量检查(如机器人检测)。由于Reddit是一个在线论坛,因此对参与研究没有地域限制。从参与者身上获取有关人口统计学特征、精益使用和心理健康障碍症状的数据。Logistic回归模型包括焦虑、抑郁和创伤作为自变量,以及协变量,以检验使用精益来处理过去30年的情绪、想法或感受 天。大多数参与者是男性(n = 1102;77.4%),平均年龄26.9岁(SD = 5.2)年。大多数参与者使用的是可待因作为瘦肉中的一种成分(n = 1060;74.5%);异丙嗪作为成分被添加31.7%的样品(n = 451),并且可待因和异丙嗪的组合作为成分被包括13.5%(n = 192)。在过去的30年里,焦虑、终身创伤暴露和女性参与者使用精益来处理情绪、想法或感受的几率增加 天。在过去的30年里,那些患有抑郁症和住房不稳定的人使用精益来处理情绪、想法或感受的几率降低了 天。这项研究通过社交媒体招募了一些人,以了解更多关于精益使用的信息,尤其是精益使用来应对心理健康症状;需要对未来的人口水平进行研究。
{"title":"Lean/Sizzurp Ingredients, Use, and Coping With Mental Health Symptoms.","authors":"Orrin D Ware","doi":"10.1177/11782218231195226","DOIUrl":"https://doi.org/10.1177/11782218231195226","url":null,"abstract":"<p><p>The substance combination of codeine and promethazine, commonly termed <i>lean</i>/<i>sizzurp</i>, has been identified as a method that some individuals use to cope with PTSD and other mental health symptomology. A sample of 1423 adults with self-reported past year lean use was recruited from substance-related Reddit pages to complete a survey about lean, including information about using lean to cope with emotions, thoughts, or feelings. To be included in the sample, persons needed to: (1) be ⩾18 years old, (2) report past year lean use, (3) complete lean use screeners, and (4) pass data quality checks (eg, bot detection). As Reddit is an online forum, no geographic restrictions were placed on study participation. Data on demographic characteristics, lean use, and mental health disorder symptomology were captured from participants. Logistic regression models included anxiety, depression, and trauma as independent variables along with covariates to examine using lean to cope with emotions, thoughts, or feelings in the past 30 days. Most participants were male (n = 1102; 77.4%), with an average age of 26.9 (SD = 5.2) years. Most participants used included codeine as an ingredient in lean (n = 1060; 74.5%); promethazine was added as an ingredient by 31.7% of the sample (n = 451), and the combination of codeine and promethazine was included as ingredients by 13.5% (n = 192) of the sample. Participants with anxiety, lifetime trauma exposure, and who were female had increased odds of using lean to cope with emotions, thoughts, or feelings in the past 30 days. Those with depression and unstable housing exhibited decreased odds of using lean to cope with emotions, thoughts, or feelings in the past 30 days. This study recruited persons via social media to learn more about lean use, especially lean use to cope with mental health symptoms; future population-level studies are needed.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231195226"},"PeriodicalIF":2.1,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/f0/10.1177_11782218231195226.PMC10517614.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41137533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding the Shared Meaning of Recovery From Substance Use Disorders: New Findings From the What is Recovery? Study. 理解物质使用障碍康复的共同意义:《什么是康复?学习
IF 2 Q3 SUBSTANCE ABUSE Pub Date : 2023-09-15 eCollection Date: 2023-01-01 DOI: 10.1177/11782218231199372
Sarah E Zemore, Kelly L Ziemer, Paul A Gilbert, Mitchell P Karno, Lee Ann Kaskutas

Background: Substance use disorder (SUD) resolution typically involves a long-term, comprehensive process of change now widely referred to as "recovery." Yet, definitions of recovery vary substantially, producing significant confusion. To support formal recovery definitions, we aimed to systematically identify recovery elements that are central to those in recovery and shared regardless of subgroup/pathway.

Methods: Data were from the What is Recovery? Study, involving a diverse, national, online survey of people in recovery (N = 9341). Surveys included a 35-item recovery measure reflecting 4 domains; participants reported whether or not each element definitely belonged in their recovery definitions. Analyses examined item endorsements overall and among 30 subgroups defined a priori (by sociodemographics, substance use characteristics, and help-seeking history) to determine where items met study-specific centrality thresholds (ie, endorsement by ⩾80% and top-10 ranking, by endorsement level). We then classified items as "core" if meeting centrality thresholds both overall and for all 30 subgroups, and "prevalent" if meeting centrality thresholds overall and for 26 to 29 subgroups.

Results: Four "core" recovery elements emerged, including a process of growth or development; being honest with oneself; taking responsibility for the things one can change; and reacting in a more balanced way. Four "prevalent" recovery elements also emerged, referencing the ability to enjoy life and handle negative feelings without substance use; abstinence and/or nonproblematic substance use; and living a life that contributes. Subgroups differing most in their endorsements included those reporting mild/moderate SUD severity; non-abstinent recovery; and no specialty treatment or mutual-help group attendance.

Conclusions: Recovery elements identified here partially reflect some stakeholder definitions, but offer greater specificity and include novel elements (eg, personal integrity). Elements may point to areas of functioning that are damaged in the addiction process and can support an addiction-free life. Findings should inform institutional recovery definitions; SUD services and research; and communications about recovery.

背景:药物使用障碍(SUD)的解决通常涉及一个长期、全面的变化过程,现在被广泛称为“恢复”。然而,恢复的定义差异很大,造成了严重的混乱。为了支持正式的恢复定义,我们旨在系统地识别恢复元素,这些恢复元素是恢复中的核心,并且无论子组/路径如何都是共享的。方法:数据来自What is recovery?这项研究涉及一项针对康复人群的全国性在线调查(N = 9341)。调查包括反映4个领域的35项恢复措施;参与者报告了每个元素是否明确属于他们的恢复定义。分析对项目背书进行了总体检查,并在先验定义的30个亚组中(通过社会人口统计学、物质使用特征和求助史)确定项目在哪些方面符合研究特定的中心性阈值(即,80%的背书和前10名的背书水平)。然后,如果总体上和所有30个亚组都达到中心性阈值,我们将项目分类为“核心”,如果整体上和26至29个亚组达到中心性门限,我们将其分类为“普遍”。结果:出现了四个“核心”恢复要素,包括成长或发展过程;对自己诚实;对自己可以改变的事情负责;并以更平衡的方式进行反应。还出现了四个“普遍”的恢复要素,即在不使用物质的情况下享受生活和处理负面情绪的能力;禁欲和/或非问题药物使用;过着有贡献的生活。背书差异最大的亚组包括报告轻度/中度SUD严重程度的亚组;非禁欲康复;没有特殊治疗或互助小组参与。结论:这里确定的恢复要素部分反映了一些利益相关者的定义,但提供了更大的特异性,并包括新的要素(如个人诚信)。元素可能指向在成瘾过程中受损的功能区域,并可以支持无成瘾生活。调查结果应为机构恢复的定义提供依据;SUD服务和研究;以及关于恢复的通信。
{"title":"Understanding the Shared Meaning of Recovery From Substance Use Disorders: New Findings From the What is Recovery? Study.","authors":"Sarah E Zemore, Kelly L Ziemer, Paul A Gilbert, Mitchell P Karno, Lee Ann Kaskutas","doi":"10.1177/11782218231199372","DOIUrl":"10.1177/11782218231199372","url":null,"abstract":"<p><strong>Background: </strong>Substance use disorder (SUD) resolution typically involves a long-term, comprehensive process of change now widely referred to as \"recovery.\" Yet, definitions of recovery vary substantially, producing significant confusion. To support formal recovery definitions, we aimed to systematically identify recovery elements that are central to those in recovery and shared regardless of subgroup/pathway.</p><p><strong>Methods: </strong>Data were from the What is Recovery? Study, involving a diverse, national, online survey of people in recovery (N = 9341). Surveys included a 35-item recovery measure reflecting 4 domains; participants reported whether or not each element definitely belonged in their recovery definitions. Analyses examined item endorsements overall and among 30 subgroups defined <i>a priori</i> (by sociodemographics, substance use characteristics, and help-seeking history) to determine where items met study-specific centrality thresholds (ie, endorsement by ⩾80% and top-10 ranking, by endorsement level). We then classified items as \"core\" if meeting centrality thresholds both overall and for all 30 subgroups, and \"prevalent\" if meeting centrality thresholds overall and for 26 to 29 subgroups.</p><p><strong>Results: </strong>Four \"core\" recovery elements emerged, including a process of growth or development; being honest with oneself; taking responsibility for the things one can change; and reacting in a more balanced way. Four \"prevalent\" recovery elements also emerged, referencing the ability to enjoy life and handle negative feelings without substance use; abstinence and/or nonproblematic substance use; and living a life that contributes. Subgroups differing most in their endorsements included those reporting mild/moderate SUD severity; non-abstinent recovery; and no specialty treatment or mutual-help group attendance.</p><p><strong>Conclusions: </strong>Recovery elements identified here partially reflect some stakeholder definitions, but offer greater specificity and include novel elements (eg, personal integrity). Elements may point to areas of functioning that are damaged in the addiction process and can support an addiction-free life. Findings should inform institutional recovery definitions; SUD services and research; and communications about recovery.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231199372"},"PeriodicalIF":2.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/91/10.1177_11782218231199372.PMC10508054.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41130143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maternal Childhood Maltreatment, Internal Working Models, and Perinatal Substance Use: Is There a Role for Hyperkatifeia? A Systematic Review. 母婴虐待、内部工作模式和围产期药物使用:是否存在高卡替菲亚的作用?系统回顾。
IF 2.1 Q3 SUBSTANCE ABUSE Pub Date : 2023-07-18 eCollection Date: 2023-01-01 DOI: 10.1177/11782218231186371
Aviva K Olsavsky, Isabella Chirico, Diab Ali, Hannah Christensen, Brianna Boggs, Lillian Svete, Katherine Ketcham, Kent Hutchison, Charles Zeanah, Nim Tottenham, Paula Riggs, C Neill Epperson

The parent-infant relationship is critical for socioemotional development and is adversely impacted by perinatal substance use. This systematic review posits that the mechanisms underlying these risks to mother-infant relationships center on 3 primary processes: (1) mothers' childhood maltreatment experiences; (2) attachment styles and consequent internal working models of interpersonal relationships; and (3) perinatal substance use. Further, the review considers the role of hyperkatifeia, or hypersensitivity to negative affect which occurs when people with substance use disorders are not using substances, and which drives the negative reinforcement in addiction. The authors performed a systematic review of articles (published 2000-2022) related to these constructs and their impact on mother-infant relationships and offspring outcomes, including original clinical research articles addressing relationships between these constructs, and excluding case studies, reviews, non-human animal studies, intervention studies, studies with fewer than 30% female-sex participants, clinical guidelines, studies limited to obstetric outcomes, mechanistic/biological studies, and studies with methodological issues precluding interpretation. Overall 1844 articles were screened, 377 were selected for full text review, and data were extracted from 157 articles. Results revealed strong relationships between mothers' childhood maltreatment experiences, less optimal internal working models, and increased risk for perinatal substance use, and importantly, all of these predictors interacted with hyperkatifeia and exerted a marked impact on mother-infant relationships with less data available on offspring outcomes. These data strongly support the need for future studies addressing the additive impact of maternal childhood maltreatment experiences, suboptimal internal working models, and perinatal substance use, with hyperkatifeia as a potential moderator, and their interacting effects on mother-infant socioemotional outcomes.

母婴关系对社会情感发展至关重要,并受到围产期药物使用的不利影响。这篇系统综述认为,母婴关系中这些风险的潜在机制集中在三个主要过程上:(1)母亲的童年虐待经历;(2) 依恋风格和由此产生的人际关系内部工作模式;(3)围产期药物使用。此外,该综述还考虑了当患有物质使用障碍的人不使用物质时发生的对负面影响的超敏反应的作用,这会导致成瘾的负面强化。作者对与这些结构及其对母婴关系和后代结果的影响有关的文章(发表于2000-2022年)进行了系统综述,包括阐述这些结构之间关系的原始临床研究文章,不包括案例研究、综述、非人动物研究、干预研究、,女性参与者少于30%的研究、临床指南、仅限于产科结果的研究、机制/生物学研究以及排除解释的方法学问题的研究。总共筛选了1844篇文章,选择377篇进行全文审查,数据从157篇文章中提取。结果显示,母亲的童年虐待经历、不太理想的内部工作模式和围产期药物使用风险增加之间存在着密切的关系,重要的是,所有这些预测因素都与高katifeia相互作用,并对母婴关系产生了显着影响,而后代结果的可用数据较少。这些数据有力地支持了未来研究的必要性,这些研究涉及母婴虐待经历、次优内部工作模式和围产期药物使用的附加影响,其中高卡替菲亚是潜在的调节因子,以及它们对母婴社会情绪结果的相互影响。
{"title":"Maternal Childhood Maltreatment, Internal Working Models, and Perinatal Substance Use: Is There a Role for Hyperkatifeia? A Systematic Review.","authors":"Aviva K Olsavsky,&nbsp;Isabella Chirico,&nbsp;Diab Ali,&nbsp;Hannah Christensen,&nbsp;Brianna Boggs,&nbsp;Lillian Svete,&nbsp;Katherine Ketcham,&nbsp;Kent Hutchison,&nbsp;Charles Zeanah,&nbsp;Nim Tottenham,&nbsp;Paula Riggs,&nbsp;C Neill Epperson","doi":"10.1177/11782218231186371","DOIUrl":"10.1177/11782218231186371","url":null,"abstract":"<p><p>The parent-infant relationship is critical for socioemotional development and is adversely impacted by perinatal substance use. This systematic review posits that the mechanisms underlying these risks to mother-infant relationships center on 3 primary processes: (1) mothers' childhood maltreatment experiences; (2) attachment styles and consequent internal working models of interpersonal relationships; and (3) perinatal substance use. Further, the review considers the role of hyperkatifeia, or hypersensitivity to negative affect which occurs when people with substance use disorders are not using substances, and which drives the negative reinforcement in addiction. The authors performed a systematic review of articles (published 2000-2022) related to these constructs and their impact on mother-infant relationships and offspring outcomes, including original clinical research articles addressing relationships between these constructs, and excluding case studies, reviews, non-human animal studies, intervention studies, studies with fewer than 30% female-sex participants, clinical guidelines, studies limited to obstetric outcomes, mechanistic/biological studies, and studies with methodological issues precluding interpretation. Overall 1844 articles were screened, 377 were selected for full text review, and data were extracted from 157 articles. Results revealed strong relationships between mothers' childhood maltreatment experiences, less optimal internal working models, and increased risk for perinatal substance use, and importantly, all of these predictors interacted with hyperkatifeia and exerted a marked impact on mother-infant relationships with less data available on offspring outcomes. These data strongly support the need for future studies addressing the additive impact of maternal childhood maltreatment experiences, suboptimal internal working models, and perinatal substance use, with hyperkatifeia as a potential moderator, and their interacting effects on mother-infant socioemotional outcomes.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231186371"},"PeriodicalIF":2.1,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d4/3b/10.1177_11782218231186371.PMC10354827.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10665728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research Compensation and Enhanced Contacts in Studies With Persons Who Use Drugs: Lessons From the COVID-19 Pandemic Demand a Reset. 研究补偿和加强与吸毒者研究的联系:新冠肺炎大流行需求重置的教训。
IF 2 Q3 SUBSTANCE ABUSE Pub Date : 2023-06-06 eCollection Date: 2023-01-01 DOI: 10.1177/11782218231179039
Matthew G Lemansky, Anna K Martin, Judith A Bernstein, Sabrina A Assoumou

Policy changes resulting from the coronavirus 2019 (COVID-19) pandemic have had a substantial and positive impact on the clinical care of persons with opioid use disorder. These innovative paradigm shifts created a ripe environment for re-evaluating traditional approaches to recruiting and retaining persons who use drugs into research studies. For example, changes to methadone prescribing requirements and authorization of buprenorphine prescriptions via telehealth have both increased access to medications. In this commentary, we contribute to ongoing conversations about the ethics of compensation for participants in addiction-related clinical research and share methods of payment that proved successful in research performed during the pandemic. We also discuss approaches to enrollment and follow-up that were implemented during the height of COVID restrictions. These approaches may mutually benefit both participants and researchers in a post-pandemic era.

2019冠状病毒病(新冠肺炎)大流行导致的政策变化对阿片类药物使用障碍患者的临床护理产生了实质性的积极影响。这些创新的范式转变为重新评估招募和留住吸毒人员进行研究的传统方法创造了一个成熟的环境。例如,美沙酮处方要求的改变和通过远程医疗授权丁丙诺啡处方都增加了获得药物的机会。在这篇评论中,我们为正在进行的关于成瘾相关临床研究参与者补偿道德的对话做出了贡献,并分享了在疫情期间成功进行的研究中证明的支付方法。我们还讨论了在新冠疫情限制最严重时期实施的入学和随访方法。在后疫情时代,这些方法可能对参与者和研究人员都有利。
{"title":"Research Compensation and Enhanced Contacts in Studies With Persons Who Use Drugs: Lessons From the COVID-19 Pandemic Demand a Reset.","authors":"Matthew G Lemansky, Anna K Martin, Judith A Bernstein, Sabrina A Assoumou","doi":"10.1177/11782218231179039","DOIUrl":"10.1177/11782218231179039","url":null,"abstract":"<p><p>Policy changes resulting from the coronavirus 2019 (COVID-19) pandemic have had a substantial and positive impact on the clinical care of persons with opioid use disorder. These innovative paradigm shifts created a ripe environment for re-evaluating traditional approaches to recruiting and retaining persons who use drugs into research studies. For example, changes to methadone prescribing requirements and authorization of buprenorphine prescriptions via telehealth have both increased access to medications. In this commentary, we contribute to ongoing conversations about the ethics of compensation for participants in addiction-related clinical research and share methods of payment that proved successful in research performed during the pandemic. We also discuss approaches to enrollment and follow-up that were implemented during the height of COVID restrictions. These approaches may mutually benefit both participants and researchers in a post-pandemic era.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231179039"},"PeriodicalIF":2.0,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/1c/10.1177_11782218231179039.PMC10251077.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10351427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Scoping Review of Risk and Protective Factors for Negative Cannabis Use Consequences. 大麻使用负面后果的风险和保护因素的范围审查。
IF 2 Q3 SUBSTANCE ABUSE Pub Date : 2023-04-07 eCollection Date: 2023-01-01 DOI: 10.1177/11782218231166622
Timothy J Grigsby, Andrea Lopez, Larisa Albers, Christopher J Rogers, Myriam Forster

Objective: Numerous reviews have examined risk and protective factors for alcohol-related negative consequences, but no equivalent review of risk and protective factors exists for cannabis-related negative consequences (CRNCs)-a gap filled by the present study. This scoping review examined survey-based research of risk and protective factors for CRNCs such as neglecting responsibilities, blacking out, or needing more cannabis.

Methods: Three databases (PubMed, PsycINFO, and Google Scholar) were searched for peer-reviewed manuscripts published between January 1, 1990, and December 31, 2021. A qualitative synthesis was performed using the matrix method and the results were organized using the socioecological model as a framework.

Results: Eighty-three studies were included in the review. There was considerable variation in measures and operationalizations of CRNCs across studies. Risk factors were identified in the intrapersonal (depression, social anxiety, PTSD, impulsivity, sensation seeking, motives, expectancies), interpersonal/community (trauma, victimization, family and peer substance use, social norms), and social/policy (education, employment, community attachment, legalization, availability of substances) domains of influence. Protective behavioral strategies were a robust protective factor for CRNCs. Males consistently reported more CRNCs than females, but there were no differences observed across race.

Conclusions: Future research should identify person- and product-specific patterns of CRNCs to refine theoretical models of cannabis misuse and addiction. Public health interventions to reduce the risk of negative consequences from cannabis should consider utilizing multilevel interventions to attenuate the cumulative risk from a combination of psychological, contextual, and social influences.

目的:许多综述研究了酒精相关负面后果的风险和保护因素,但没有对大麻相关负面后果(crnc)的风险和保护因素进行相应的综述-本研究填补了这一空白。这一范围审查审查了基于调查的crnc风险和保护因素的研究,如忽视责任、停电或需要更多的大麻。方法:检索PubMed、PsycINFO和Google Scholar三个数据库,检索1990年1月1日至2021年12月31日发表的同行评议稿件。使用矩阵法进行定性综合,并使用社会生态模型作为框架组织结果。结果:83项研究被纳入综述。在不同的研究中,crnc的测量和操作存在相当大的差异。风险因素在人际关系(抑郁、社交焦虑、创伤后应激障碍、冲动、寻求感觉、动机、期望)、人际/社区(创伤、受害、家庭和同伴物质使用、社会规范)和社会/政策(教育、就业、社区依恋、合法化、物质可得性)的影响领域中被确定。保护行为策略是crnc的一个强有力的保护因素。男性报告的crnc始终多于女性,但在种族间没有观察到差异。结论:未来的研究应该确定crnc的个人和产品特定模式,以完善大麻滥用和成瘾的理论模型。旨在减少大麻负面后果风险的公共卫生干预措施应考虑利用多层次干预措施,以减轻心理、环境和社会影响综合造成的累积风险。
{"title":"A Scoping Review of Risk and Protective Factors for Negative Cannabis Use Consequences.","authors":"Timothy J Grigsby, Andrea Lopez, Larisa Albers, Christopher J Rogers, Myriam Forster","doi":"10.1177/11782218231166622","DOIUrl":"10.1177/11782218231166622","url":null,"abstract":"<p><strong>Objective: </strong>Numerous reviews have examined risk and protective factors for alcohol-related negative consequences, but no equivalent review of risk and protective factors exists for cannabis-related negative consequences (CRNCs)-a gap filled by the present study. This scoping review examined survey-based research of risk and protective factors for CRNCs such as neglecting responsibilities, blacking out, or needing more cannabis.</p><p><strong>Methods: </strong>Three databases (PubMed, PsycINFO, and Google Scholar) were searched for peer-reviewed manuscripts published between January 1, 1990, and December 31, 2021. A qualitative synthesis was performed using the matrix method and the results were organized using the socioecological model as a framework.</p><p><strong>Results: </strong>Eighty-three studies were included in the review. There was considerable variation in measures and operationalizations of CRNCs across studies. Risk factors were identified in the <i>intrapersonal</i> (depression, social anxiety, PTSD, impulsivity, sensation seeking, motives, expectancies), <i>interpersonal/community</i> (trauma, victimization, family and peer substance use, social norms), and <i>social/policy</i> (education, employment, community attachment, legalization, availability of substances) domains of influence. Protective behavioral strategies were a robust protective factor for CRNCs. Males consistently reported more CRNCs than females, but there were no differences observed across race.</p><p><strong>Conclusions: </strong>Future research should identify person- and product-specific patterns of CRNCs to refine theoretical models of cannabis misuse and addiction. Public health interventions to reduce the risk of negative consequences from cannabis should consider utilizing multilevel interventions to attenuate the cumulative risk from a combination of psychological, contextual, and social influences.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231166622"},"PeriodicalIF":2.0,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6b/4e/10.1177_11782218231166622.PMC10087658.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9304996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Focused Screening and Clinical Intervention with Streamlined Outpatient Linkage for Hospitalized Patients with Opioid Use Disorder Experiencing Homelessness. 针对无家可归的阿片类药物使用障碍住院患者的重点筛查和临床干预,以及简化的门诊链接。
IF 2 Q3 SUBSTANCE ABUSE Pub Date : 2023-04-06 eCollection Date: 2023-01-01 DOI: 10.1177/11782218231166382
Sandra Oreper, Allison Bond, Marilyn Bazinski, Matthew Tierney, Margaret Fang, Sujatha Sankaran, Aksharananda Rambachan

Background: Patients experiencing homelessness have higher rates of substance use and related mortality, often driven by opioid overdose. Conversely, opioid use disorder (OUD) is a leading risk factor for homelessness. Our goal was to test the efficacy of an electronic health record (EHR) screen in identifying this vulnerable population during hospitalization and to assess the feasibility of a bundled intervention in improving opioid safety.

Methods: We assessed patients' housing status, substance use, previous MOUD treatment, barriers to MOUD treatment and readiness to take MOUD in and out of the hospital. For each post discharge follow up call, patients were asked about their MOUD status, barriers accessing treatment, current substance use, and housing status. We also assessed team members perceptions and experiences of the study.

Results: We enrolled 32 patients with housing insecurity and OUD. The mean age was 44, the majority self-identified as male (78%), and mostly as White (56%) or Black (38%). At each follow up within the 6-months post-discharge, reach rates were low: 40% of enrollees answered at least 1 call and the highest reach rate (31% of patients) occurred at week 4. At the third and sixth-month follow ups, >50% of subjects still taking MOUD were also using opioids.

Conclusion: Our clinician augmented EHR screen accurately identified inpatients experiencing OUD and PEH. This intervention showed high rates of attrition among enrolled patients, even after providing cellphones. The majority of patients who were reached remained adherent to MOUD though they reported significant barriers.

背景:无家可归患者的药物使用率和相关死亡率较高,通常是由阿片类药物过量引起的。相反,阿片类药物使用障碍(OUD)是导致无家可归的主要风险因素。我们的目标是测试电子健康记录(EHR)筛查在住院期间识别这一弱势群体的有效性,并评估捆绑干预在改善阿片类药物安全性方面的可行性:我们评估了患者的住房状况、药物使用情况、之前的牟利治疗情况、牟利治疗的障碍以及在医院内外服用牟利药物的准备情况。在每次出院后的随访电话中,我们都会询问患者的 MOUD 状况、获得治疗的障碍、目前的药物使用情况以及住房状况。我们还评估了团队成员对这项研究的看法和经验:我们招募了 32 名住房无保障和 OUD 患者。他们的平均年龄为 44 岁,大多数自我认同为男性(78%),大多数为白人(56%)或黑人(38%)。在出院后 6 个月内的每次随访中,联系率都很低:40% 的参加者至少接听了一次电话,联系率最高的一次(31% 的患者)发生在第 4 周。在第 3 个月和第 6 个月的随访中,仍在服用 MOUD 的受试者中有 50% 以上还在使用阿片类药物:结论:我们的临床医生增强型电子病历筛查能准确识别患有 OUD 和 PEH 的住院病人。即使在提供手机后,这项干预措施在入组患者中的流失率也很高。大多数接受干预的患者仍坚持接受 MOUD 治疗,尽管他们报告称存在重大障碍。
{"title":"A Focused Screening and Clinical Intervention with Streamlined Outpatient Linkage for Hospitalized Patients with Opioid Use Disorder Experiencing Homelessness.","authors":"Sandra Oreper, Allison Bond, Marilyn Bazinski, Matthew Tierney, Margaret Fang, Sujatha Sankaran, Aksharananda Rambachan","doi":"10.1177/11782218231166382","DOIUrl":"10.1177/11782218231166382","url":null,"abstract":"<p><strong>Background: </strong>Patients experiencing homelessness have higher rates of substance use and related mortality, often driven by opioid overdose. Conversely, opioid use disorder (OUD) is a leading risk factor for homelessness. Our goal was to test the efficacy of an electronic health record (EHR) screen in identifying this vulnerable population during hospitalization and to assess the feasibility of a bundled intervention in improving opioid safety.</p><p><strong>Methods: </strong>We assessed patients' housing status, substance use, previous MOUD treatment, barriers to MOUD treatment and readiness to take MOUD in and out of the hospital. For each post discharge follow up call, patients were asked about their MOUD status, barriers accessing treatment, current substance use, and housing status. We also assessed team members perceptions and experiences of the study.</p><p><strong>Results: </strong>We enrolled 32 patients with housing insecurity and OUD. The mean age was 44, the majority self-identified as male (78%), and mostly as White (56%) or Black (38%). At each follow up within the 6-months post-discharge, reach rates were low: 40% of enrollees answered at least 1 call and the highest reach rate (31% of patients) occurred at week 4. At the third and sixth-month follow ups, >50% of subjects still taking MOUD were also using opioids.</p><p><strong>Conclusion: </strong>Our clinician augmented EHR screen accurately identified inpatients experiencing OUD and PEH. This intervention showed high rates of attrition among enrolled patients, even after providing cellphones. The majority of patients who were reached remained adherent to MOUD though they reported significant barriers.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231166382"},"PeriodicalIF":2.0,"publicationDate":"2023-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5b/f5/10.1177_11782218231166382.PMC10084569.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9304497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Occupation-Based Lifestyle Lecture Intervention as Part of Inpatient Addiction Recovery Treatment: Exploring Occupational Performance, Balance and Personal Recovery. 以职业为基础的生活方式讲座干预,作为住院戒毒治疗的一部分:探索职业表现、平衡和个人康复。
IF 2 Q3 SUBSTANCE ABUSE Pub Date : 2023-03-31 eCollection Date: 2023-01-01 DOI: 10.1177/11782218231165123
Deirdre Ryan, Marie Naughton, Meabh de Faoite, Tara Dowd, Ann-Marie Morrissey

Introduction: Substance use disorders (SUDs) and addictive behaviours are growing problems which negatively impact health and wellbeing. Occupational therapy can support recovery by facilitating engagement in everyday activities that promote health. To date, the inclusion of occupational therapy in addiction recovery is limited and the evidence base for occupation-focused interventions is lacking. This study explores the impact of an occupational therapy-led intervention on self-reported occupational performance and occupational balance issues for people living with SUDs within an inpatient addiction service.

Methodology: A quantitative pre and post-test study was implemented. The Canadian Personal Recovery Outcome Measure (C-PROM) was the sole outcome measure. The C-PROM is a self-report measure which aims to measure personal views of recovery based on rating activity engagement. The cohort of participants were recruited from referrals into 2 inpatient addiction recovery treatment programmes using purposive sampling. Descriptive statistics were run, and a Wilcoxon Signed Rank Test was used to analyse pre and post-test scoring.

Results: Sixteen participants (9 male and 7 female) completed the intervention and outcome measure. The majority of participants (31.3%, n = 5) were between 45 and 54 years old. 25% of the sample (n = 4) were in the 35 to 44 age bracket while 18.8% (n = 3) were aged 55 to 64. The majority of participants (68.8%, n = 11) reported substance misuse as their main healthcare concern. The mean score on the C-PROM was significantly higher after participants received the intervention when compared with baseline scoring.

Conclusion: Following engagement with an occupational therapist-led intervention participants reported increased engagement in activities and occupational performance. Participants also reported improved occupational balance and increased awareness of personal recovery needs. Further research is required to explore the effectiveness of this intervention in larger samples and to explore the transferability and sustainability of skills post discharge.

导言:药物使用障碍(SUD)和成瘾行为是日益严重的问题,对健康和幸福造成了负面影响。职业疗法可以通过促进参与能增进健康的日常活动来支持康复。迄今为止,职业疗法在成瘾康复中的应用还很有限,以职业为重点的干预措施也缺乏证据基础。本研究探讨了以职业疗法为主导的干预措施对住院戒毒服务中患有药物依赖性精神疾病的患者自我报告的职业表现和职业平衡问题的影响:方法:实施了一项定量的前后测试研究。加拿大个人康复结果测量(C-PROM)是唯一的结果测量方法。C-PROM 是一种自我报告测量方法,旨在根据参与活动的评级来测量个人对康复的看法。研究人员通过有目的的抽样,从两个住院病人戒毒治疗项目的转诊病人中招募。研究人员进行了描述性统计,并使用 Wilcoxon Signed Rank Test 对测试前后的得分进行了分析:16 名参与者(9 男 7 女)完成了干预和结果测量。大多数参与者(31.3%,n = 5)的年龄在 45 至 54 岁之间。25%的参与者(4 人)年龄在 35 至 44 岁之间,18.8% 的参与者(3 人)年龄在 55 至 64 岁之间。大多数参与者(68.8%,n = 11)表示滥用药物是他们主要的医疗保健问题。与基线得分相比,参与者接受干预后的C-PROM平均得分明显提高:结论:接受职业治疗师指导的干预后,参与者表示参与活动的程度和职业表现均有所提高。参与者还表示职业平衡得到了改善,并提高了对个人康复需求的认识。还需要进一步的研究来探讨这种干预在更大样本中的有效性,并探讨技能在出院后的可转移性和可持续性。
{"title":"An Occupation-Based Lifestyle Lecture Intervention as Part of Inpatient Addiction Recovery Treatment: Exploring Occupational Performance, Balance and Personal Recovery.","authors":"Deirdre Ryan, Marie Naughton, Meabh de Faoite, Tara Dowd, Ann-Marie Morrissey","doi":"10.1177/11782218231165123","DOIUrl":"10.1177/11782218231165123","url":null,"abstract":"<p><strong>Introduction: </strong>Substance use disorders (SUDs) and addictive behaviours are growing problems which negatively impact health and wellbeing. Occupational therapy can support recovery by facilitating engagement in everyday activities that promote health. To date, the inclusion of occupational therapy in addiction recovery is limited and the evidence base for occupation-focused interventions is lacking. This study explores the impact of an occupational therapy-led intervention on self-reported occupational performance and occupational balance issues for people living with SUDs within an inpatient addiction service.</p><p><strong>Methodology: </strong>A quantitative pre and post-test study was implemented. The Canadian Personal Recovery Outcome Measure (C-PROM) was the sole outcome measure. The C-PROM is a self-report measure which aims to measure personal views of recovery based on rating activity engagement. The cohort of participants were recruited from referrals into 2 inpatient addiction recovery treatment programmes using purposive sampling. Descriptive statistics were run, and a Wilcoxon Signed Rank Test was used to analyse pre and post-test scoring.</p><p><strong>Results: </strong>Sixteen participants (9 male and 7 female) completed the intervention and outcome measure. The majority of participants (31.3%, n = 5) were between 45 and 54 years old. 25% of the sample (n = 4) were in the 35 to 44 age bracket while 18.8% (n = 3) were aged 55 to 64. The majority of participants (68.8%, n = 11) reported substance misuse as their main healthcare concern. The mean score on the C-PROM was significantly higher after participants received the intervention when compared with baseline scoring.</p><p><strong>Conclusion: </strong>Following engagement with an occupational therapist-led intervention participants reported increased engagement in activities and occupational performance. Participants also reported improved occupational balance and increased awareness of personal recovery needs. Further research is required to explore the effectiveness of this intervention in larger samples and to explore the transferability and sustainability of skills post discharge.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231165123"},"PeriodicalIF":2.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c6/5a/10.1177_11782218231165123.PMC10068992.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9257806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing COVID-19-related Morbidity and Mortality Between Patients With and Without Substance Use Disorders: A Retrospective Cohort Study. 比较有药物滥用障碍和无药物滥用障碍患者的 COVID-19 相关发病率和死亡率:回顾性队列研究。
IF 2 Q3 SUBSTANCE ABUSE Pub Date : 2023-03-22 eCollection Date: 2023-01-01 DOI: 10.1177/11782218231160014
Angela McLaughlin, Rebecca Burns, Morgan Ryan, Wafaa Abbasi, Leah Harvey, Jacqueline Hicks, Pranay Sinha, Sabrina A Assoumou

Objectives: People with substance use disorders (SUD) are suggested to have higher risk of hospitalization, intubation, or death from coronavirus disease 2019 (COVID-19), although data are mixed. Little is known about other COVID-19-related complications in this group. We compared morbidity and mortality among individuals with and without SUD who were admitted to an urban safety net hospital with COVID-19 early in the pandemic, contemporaneous to other published studies on this subject.

Methods: We performed a retrospective study of patients ⩾18 years old admitted with COVID-19 from March 16th to April 8th, 2020. SUD included alcohol, opioid, cocaine, amphetamine, and benzodiazepine use disorders and was identified using diagnostic codes, free text clinical documentation, and urine drug screens. The primary outcome was inpatient mortality. Secondary outcomes included clinical complications (eg, secondary infections, venous thromboembolism) and resource utilization (eg, mechanical ventilation, length of stay). We used multivariable regression to assess the relationship between SUD and mortality.

Results: Of 409 patients, the mean age was 56 years and 13.7% had SUD. Those with SUD were more likely to be male, have experienced homelessness, have pulmonary disease or hepatitis C, or use tobacco or cannabis. After multivariable analysis, SUD was not associated with mortality (aOR 1.03; 95% CI, 0.31-3.10). Secondary outcomes were also similar between groups.

Conclusions: Our findings suggest that persons with and without SUD have similar COVID-19-related outcomes. Previously reported increased COVID-19 complications may be from medical comorbidities.

目的:有研究表明,有药物使用障碍(SUD)的人因冠状病毒病 2019(COVID-19)住院、插管或死亡的风险较高,但数据不一。人们对这一群体中与 COVID-19 相关的其他并发症知之甚少。我们比较了在大流行早期因 COVID-19 而入住城市安全网医院的 SUD 患者和非 SUD 患者的发病率和死亡率,这与其他已发表的相关研究结果是同步的:我们对 2020 年 3 月 16 日至 4 月 8 日期间因 COVID-19 入院的 18 岁以下患者进行了回顾性研究。SUD 包括酒精、阿片类药物、可卡因、苯丙胺和苯二氮卓类药物使用障碍,并通过诊断代码、自由文本临床文件和尿液药物筛查进行识别。主要结果为住院病人死亡率。次要结果包括临床并发症(如继发感染、静脉血栓栓塞)和资源利用率(如机械通气、住院时间)。我们采用多变量回归法评估 SUD 与死亡率之间的关系:在 409 名患者中,平均年龄为 56 岁,13.7% 患有 SUD。有 SUD 的患者更有可能是男性、无家可归者、患有肺部疾病或丙型肝炎、吸烟或吸食大麻。经过多变量分析,SUD 与死亡率无关(aOR 1.03;95% CI,0.31-3.10)。各组之间的次要结果也相似:我们的研究结果表明,有 SUD 和没有 SUD 的人群具有相似的 COVID-19 相关结果。之前报道的 COVID-19 并发症增加可能是由于合并症引起的。
{"title":"Comparing COVID-19-related Morbidity and Mortality Between Patients With and Without Substance Use Disorders: A Retrospective Cohort Study.","authors":"Angela McLaughlin, Rebecca Burns, Morgan Ryan, Wafaa Abbasi, Leah Harvey, Jacqueline Hicks, Pranay Sinha, Sabrina A Assoumou","doi":"10.1177/11782218231160014","DOIUrl":"10.1177/11782218231160014","url":null,"abstract":"<p><strong>Objectives: </strong>People with substance use disorders (SUD) are suggested to have higher risk of hospitalization, intubation, or death from coronavirus disease 2019 (COVID-19), although data are mixed. Little is known about other COVID-19-related complications in this group. We compared morbidity and mortality among individuals with and without SUD who were admitted to an urban safety net hospital with COVID-19 early in the pandemic, contemporaneous to other published studies on this subject.</p><p><strong>Methods: </strong>We performed a retrospective study of patients ⩾18 years old admitted with COVID-19 from March 16th to April 8th, 2020. SUD included alcohol, opioid, cocaine, amphetamine, and benzodiazepine use disorders and was identified using diagnostic codes, free text clinical documentation, and urine drug screens. The primary outcome was inpatient mortality. Secondary outcomes included clinical complications (eg, secondary infections, venous thromboembolism) and resource utilization (eg, mechanical ventilation, length of stay). We used multivariable regression to assess the relationship between SUD and mortality.</p><p><strong>Results: </strong>Of 409 patients, the mean age was 56 years and 13.7% had SUD. Those with SUD were more likely to be male, have experienced homelessness, have pulmonary disease or hepatitis C, or use tobacco or cannabis. After multivariable analysis, SUD was not associated with mortality (aOR 1.03; 95% CI, 0.31-3.10). Secondary outcomes were also similar between groups.</p><p><strong>Conclusions: </strong>Our findings suggest that persons with and without SUD have similar COVID-19-related outcomes. Previously reported increased COVID-19 complications may be from medical comorbidities.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231160014"},"PeriodicalIF":2.0,"publicationDate":"2023-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1c/77/10.1177_11782218231160014.PMC10034287.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9560577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Buprenorphine Dose and the Urine "Norbuprenorphine" to "Creatinine" Ratio: Revised. 丁丙诺啡剂量和尿“诺丙诺啡”与“肌酐”比值之间的关系:修订。
IF 2.1 Q3 SUBSTANCE ABUSE Pub Date : 2023-03-13 eCollection Date: 2023-01-01 DOI: 10.1177/11782218231153748
Hiroko Furo, Timothy Wiegand, Meenakshi Rani, Diane G Schwartz, Ross W Sullivan, Peter L Elkin
<p><strong>Background: </strong>Utilizing a 1-year chart review as the data, Furo et al. conducted a research study on an association between buprenorphine dose and the urine "norbuprenorphine" to "creatinine" ratio and found significant differences in the ratio among 8-, 12-, and 16-mg/day groups with an analysis of variance (ANOVA) test. This study expands the data for a 2-year chart review and is intended to delineate an association between buprenorphine dose and the urine "norbuprenorphine" to "creatinine" ratio with a higher statistical power.</p><p><strong>Methods: </strong>This study performed a 2-year chart review of data for the patients living in a halfway house setting, where their drug administration was closely monitored. The patients were on buprenorphine prescribed at an outpatient clinic for opioid use disorder (OUD), and their buprenorphine prescription and dispensing information were confirmed by the New York Prescription Drug Monitoring Program (PDMP). Urine test results in the electronic health record (EHR) were reviewed, focusing on the "buprenorphine," "norbuprenorphine," and "creatinine" levels. The Kruskal-Wallis <i>H</i> and Mann-Whitney <i>U</i> tests were performed to examine an association between buprenorphine dose and the "norbuprenorphine" to "creatinine" ratio.</p><p><strong>Results: </strong>This study included 371 urine samples from 61 consecutive patients and analyzed the data in a manner similar to that described in the study by Furo et al. This study had similar findings with the following exceptions: (1) a mean buprenorphine dose of 11.0 ± 3.8 mg/day with a range of 2 to 20 mg/day; (2) exclusion of 6 urine samples with "creatinine" level <20 mg/dL; (3) minimum "norbuprenorphine" to "creatinine" ratios in the 8-, 12-, and 16-mg/day groups of 0.44 × 10<sup>-4</sup> (n = 68), 0.1 × 10<sup>-4</sup> (n = 133), and 1.37 × 10<sup>-4</sup> (n = 82), respectively; however, after removing the 2 lowest outliers, the minimum "norbuprenorphine" to "creatinine" ratio in the 12-mg/day group was 1.6 × 10<sup>-4</sup>, similar to the findings in the previous study; and (4) a significant association between buprenorphine dose and the urine "norbuprenorphine" to "creatinine" ratios from the Kruskal-Wallis test (<i>P</i> < .01). In addition, the median "norbuprenorphine" to "creatinine" ratio had a strong association with buprenorphine dose, and this association could be formulated as: [y = 2.266 ln(<i>x</i>) + 0.8211]. In other words, the median ratios in 8-, 12-, and 16-mg/day groups were 5.53 × 10<sup>-4</sup>, 6.45 × 10<sup>-4</sup>, and 7.10 × 10<sup>-4</sup>, respectively. Therefore, any of the following features should alert providers to further investigate patient treatment compliance: (1) inappropriate substance(s) in urine sample; (2) "creatinine" level <20 mg/dL; (3) "buprenorphine" to "norbuprenorphine" ratio >50:1; (4) buprenorphine dose >24 mg/day; or (5) "norbuprenorphine" to "creatinine" ratios <0.5 × 10<sup>-4</
背景:Furo等人利用一年的图表回顾作为数据,对丁丙诺啡剂量与尿液中“诺丁丙诺啡”与“肌酐”比率之间的关系进行了一项研究,并通过方差分析(ANOVA)检验发现,8、12和16 mg/天组之间的比率存在显著差异。这项研究扩展了2年图表审查的数据,旨在以更高的统计功效描述丁丙诺啡剂量与尿液“丁丙诺诺啡”与“肌酸酐”比率之间的关联。方法:本研究对居住在中途之家的患者的数据进行了为期2年的图表审查,在那里他们的药物管理受到密切监测。这些患者在门诊接受了阿片类药物使用障碍(OUD)的丁丙诺啡处方,他们的丁丙诺处方和配药信息得到了纽约处方药监测计划(PDMP)的确认。对电子健康记录(EHR)中的尿液检测结果进行了审查,重点是“丁丙诺啡”、“丁丙诺啡”和“肌酸酐”水平。Kruskal-Wallis H和Mann-Whitney U检验是为了检验丁丙诺啡剂量与“去丁丙诺菲”与“肌酸酐”比率之间的相关性。结果:这项研究包括61名连续患者的371份尿液样本,并以与Furo等人研究中描述的类似的方式分析数据。这项研究有类似的发现,但以下例外:(1)丁丙诺啡的平均剂量为11.0 ± 3.8 mg/天,范围为2至20 mg/天;(2) 排除6份“肌酸酐”水平为-4(n = 68),0.1 × 10-4(n = 133)和1.37 × 10-4(n = 82);然而,在去除2个最低的异常值后,12毫克/天组的最小“丁丙诺啡”与“肌酸酐”比率为1.6 × 10-4,与之前的研究结果相似;和(4)Kruskal-Wallis检验的丁丙诺啡剂量与尿液“丁丙诺诺啡”与“肌酐”比值之间存在显著相关性(P x) + 0.8211]。换句话说,8、12和16 mg/天组的中位比值为5.53 × 10-4,6.45 × 10-4和7.10 × 10-4。因此,以下任何特征都应提醒提供者进一步调查患者的治疗依从性:(1)尿样中的不适当物质;(2) “肌酸酐”水平50:1;(4) 丁丙诺啡剂量>24 mg/天;或(5)“丁丙诺啡”与“肌酸酐”的比率-在8岁的患者中为4 mg/天或-4 mg/天或更高。结论:使用扩展的数据集,本研究的结果证实了先前研究中关于丁丙诺啡剂量与“丁丙诺诺啡”与“肌酸酐”比率之间相关性的结果。此外,这项研究描绘了一个更清晰的关系,重点关注不同丁丙诺啡剂量组中“丁丙诺诺啡”与“肌酸酐”的中位数比率。这些结果可以帮助提供者更准确地解释尿检结果,并将其应用于门诊阿片类药物治疗项目,以获得最佳治疗结果。
{"title":"Association Between Buprenorphine Dose and the Urine \"Norbuprenorphine\" to \"Creatinine\" Ratio: Revised.","authors":"Hiroko Furo,&nbsp;Timothy Wiegand,&nbsp;Meenakshi Rani,&nbsp;Diane G Schwartz,&nbsp;Ross W Sullivan,&nbsp;Peter L Elkin","doi":"10.1177/11782218231153748","DOIUrl":"10.1177/11782218231153748","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Utilizing a 1-year chart review as the data, Furo et al. conducted a research study on an association between buprenorphine dose and the urine \"norbuprenorphine\" to \"creatinine\" ratio and found significant differences in the ratio among 8-, 12-, and 16-mg/day groups with an analysis of variance (ANOVA) test. This study expands the data for a 2-year chart review and is intended to delineate an association between buprenorphine dose and the urine \"norbuprenorphine\" to \"creatinine\" ratio with a higher statistical power.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study performed a 2-year chart review of data for the patients living in a halfway house setting, where their drug administration was closely monitored. The patients were on buprenorphine prescribed at an outpatient clinic for opioid use disorder (OUD), and their buprenorphine prescription and dispensing information were confirmed by the New York Prescription Drug Monitoring Program (PDMP). Urine test results in the electronic health record (EHR) were reviewed, focusing on the \"buprenorphine,\" \"norbuprenorphine,\" and \"creatinine\" levels. The Kruskal-Wallis &lt;i&gt;H&lt;/i&gt; and Mann-Whitney &lt;i&gt;U&lt;/i&gt; tests were performed to examine an association between buprenorphine dose and the \"norbuprenorphine\" to \"creatinine\" ratio.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;This study included 371 urine samples from 61 consecutive patients and analyzed the data in a manner similar to that described in the study by Furo et al. This study had similar findings with the following exceptions: (1) a mean buprenorphine dose of 11.0 ± 3.8 mg/day with a range of 2 to 20 mg/day; (2) exclusion of 6 urine samples with \"creatinine\" level &lt;20 mg/dL; (3) minimum \"norbuprenorphine\" to \"creatinine\" ratios in the 8-, 12-, and 16-mg/day groups of 0.44 × 10&lt;sup&gt;-4&lt;/sup&gt; (n = 68), 0.1 × 10&lt;sup&gt;-4&lt;/sup&gt; (n = 133), and 1.37 × 10&lt;sup&gt;-4&lt;/sup&gt; (n = 82), respectively; however, after removing the 2 lowest outliers, the minimum \"norbuprenorphine\" to \"creatinine\" ratio in the 12-mg/day group was 1.6 × 10&lt;sup&gt;-4&lt;/sup&gt;, similar to the findings in the previous study; and (4) a significant association between buprenorphine dose and the urine \"norbuprenorphine\" to \"creatinine\" ratios from the Kruskal-Wallis test (&lt;i&gt;P&lt;/i&gt; &lt; .01). In addition, the median \"norbuprenorphine\" to \"creatinine\" ratio had a strong association with buprenorphine dose, and this association could be formulated as: [y = 2.266 ln(&lt;i&gt;x&lt;/i&gt;) + 0.8211]. In other words, the median ratios in 8-, 12-, and 16-mg/day groups were 5.53 × 10&lt;sup&gt;-4&lt;/sup&gt;, 6.45 × 10&lt;sup&gt;-4&lt;/sup&gt;, and 7.10 × 10&lt;sup&gt;-4&lt;/sup&gt;, respectively. Therefore, any of the following features should alert providers to further investigate patient treatment compliance: (1) inappropriate substance(s) in urine sample; (2) \"creatinine\" level &lt;20 mg/dL; (3) \"buprenorphine\" to \"norbuprenorphine\" ratio &gt;50:1; (4) buprenorphine dose &gt;24 mg/day; or (5) \"norbuprenorphine\" to \"creatinine\" ratios &lt;0.5 × 10&lt;sup&gt;-4&lt;/","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231153748"},"PeriodicalIF":2.1,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0b/88/10.1177_11782218231153748.PMC10014968.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9499456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychoactive Substance Use Disorder in HIV-Infected Adolescents in Botswana: A Comparison Between the Congenitally Infected and Behaviorally Infected Adolescents. 博茨瓦纳感染艾滋病毒青少年的精神活性物质使用障碍:先天感染和行为感染青少年的比较。
IF 2 Q3 SUBSTANCE ABUSE Pub Date : 2023-02-27 eCollection Date: 2023-01-01 DOI: 10.1177/11782218231152818
Anthony A Olashore, Saeeda Paruk, Merrian Brooks, Bonginkosi Chiliza

Substance use is a major obstacle to preventing and managing HIV among adolescents, who account for 30% of new infections in many parts of the world, including Botswana. Unfortunately, there is a paucity of data on adolescent substance use, especially in the region. Therefore, this study aimed to determine the pattern of psychoactive substance use in adolescents living with HIV (ALWHIV). It also aimed to compare and explore the pattern of substance use disorders and associated factors between congenitally infected adolescents (CIAs) and behaviorally infected adolescents (BIAs). Six hundred and thirty-four ALWHIV were interviewed using a sociodemographic questionnaire, the WHO drug questionnaire, and DSM-5 criteria for substance use disorder. The participants' mean age (SD) was 17.69 (1.6) years, with a male predominance (n = 336, 53%), and the majority (n = 411, 64.8%) were CIAs. Alcohol was the most used substance among the participants, with 15.8% admitting to its current use. The BIAs were more likely to have SUD (χ2 = 17.2, P < .01), use more than one substance (χ2 = 20.3, P < .01), and more likely to use all psychoactive substances except for inhalants. In the CIAs, regular participation in religious activities was negatively associated with SUD (AOR = 0.36; 95% CI: 0.17-0.77), while struggling with HIV status acceptance was positively associated with SUD (AOR = 2.54; 95% CI: 1.15-5.61) in the BIAs. This study showed a huge burden and similar pattern of substance use disorders among the ALWHIV in Botswana, as reported elsewhere. It also identified the dissimilarities between the BIAs and CIAs regarding substance-related issues and suggested the need for differentiated care.

在包括博茨瓦纳在内的世界许多地方,青少年占新感染者的 30%,使用药物是预防和控制青少年感染艾滋病毒的主要障碍。遗憾的是,有关青少年使用药物的数据很少,尤其是在该地区。因此,本研究旨在确定感染艾滋病毒的青少年(ALWHIV)使用精神活性物质的模式。本研究还旨在比较和探讨先天性感染青少年(CIAs)和行为感染青少年(BIAs)的药物使用障碍模式及相关因素。研究使用社会人口学问卷、世界卫生组织毒品问卷和 DSM-5 药物使用障碍标准对 634 名 ALWHIV 进行了访谈。参与者的平均年龄(标清)为 17.69 (1.6)岁,男性居多(n = 336,53%),大多数(n = 411,64.8%)为感染者。酒精是参与者使用最多的物质,15.8% 的参与者承认目前正在使用酒精。BIAs 更有可能患有 SUD(χ2 = 17.2,P 2 = 20.3,P
{"title":"Psychoactive Substance Use Disorder in HIV-Infected Adolescents in Botswana: A Comparison Between the Congenitally Infected and Behaviorally Infected Adolescents.","authors":"Anthony A Olashore, Saeeda Paruk, Merrian Brooks, Bonginkosi Chiliza","doi":"10.1177/11782218231152818","DOIUrl":"10.1177/11782218231152818","url":null,"abstract":"<p><p>Substance use is a major obstacle to preventing and managing HIV among adolescents, who account for 30% of new infections in many parts of the world, including Botswana. Unfortunately, there is a paucity of data on adolescent substance use, especially in the region. Therefore, this study aimed to determine the pattern of psychoactive substance use in adolescents living with HIV (ALWHIV). It also aimed to compare and explore the pattern of substance use disorders and associated factors between congenitally infected adolescents (CIAs) and behaviorally infected adolescents (BIAs). Six hundred and thirty-four ALWHIV were interviewed using a sociodemographic questionnaire, the WHO drug questionnaire, and DSM-5 criteria for substance use disorder. The participants' mean age (SD) was 17.69 (1.6) years, with a male predominance (n = 336, 53%), and the majority (n = 411, 64.8%) were CIAs. Alcohol was the most used substance among the participants, with 15.8% admitting to its current use. The BIAs were more likely to have SUD (χ<sup>2</sup> = 17.2, <i>P</i> < .01), use more than one substance (χ<sup>2</sup> = 20.3, <i>P</i> < .01), and more likely to use all psychoactive substances except for inhalants. In the CIAs, regular participation in religious activities was negatively associated with SUD (AOR = 0.36; 95% CI: 0.17-0.77), while struggling with HIV status acceptance was positively associated with SUD (AOR = 2.54; 95% CI: 1.15-5.61) in the BIAs. This study showed a huge burden and similar pattern of substance use disorders among the ALWHIV in Botswana, as reported elsewhere. It also identified the dissimilarities between the BIAs and CIAs regarding substance-related issues and suggested the need for differentiated care.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231152818"},"PeriodicalIF":2.0,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/4a/10.1177_11782218231152818.PMC9974603.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9395929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Substance Abuse: Research and Treatment
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1